03:48 AM EDT, 07/01/2024 (MT Newswires) -- Mesoblast (MESO) said Monday it would file a biologics license application with the US Food and Drug Administration next week for approval of Ryoncil, or remestemcel-L, to treat children with steroid-refractory acute graft versus host disease.
Price: 6.66, Change: -0.15, Percent Change: -2.20